DrugPatentWatch Database Preview
Drugs in Development Information for AT7519
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug AT7519?
AT7519 is an investigational drug.
There have been 5 clinical trials for AT7519.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.
The most common disease conditions in clinical trials are Lymphoma, Leukemia, Lymphoid, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are Astex Pharmaceuticals, NCIC Clinical Trials Group, and National Cancer Institute (NCI).
There are twenty-four US patents protecting this investigational drug and two hundred and fifty-three international patents.
Summary for AT7519
| US Patents | 24 |
| International Patents | 253 |
| US Patent Applications | 87 |
| WIPO Patent Applications | 71 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2012-08-01) |
| Vendors | 62 |
Recent Clinical Trials for AT7519
| Title | Sponsor | Phase |
|---|---|---|
| Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | National Cancer Institute (NCI) | Phase 1 |
| A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia | Astex Pharmaceuticals | Phase 2 |
| A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia | NCIC Clinical Trials Group | Phase 2 |
Clinical Trial Summary for AT7519
Top disease conditions for AT7519
Top clinical trial sponsors for AT7519
US Patents for AT7519
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AT7519 | Start Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | Start Trial |
| AT7519 | Start Trial | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| AT7519 | Start Trial | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (Basel, CH) | Start Trial |
| AT7519 | Start Trial | Triazolopyrimidine compounds and uses thereof | Novartis AG (Basel, CH) | Start Trial |
| AT7519 | Start Trial | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| AT7519 | Start Trial | Low, immune enhancing, dose MTOR inhibitors and uses thereof | Novartis AG (Basel, CH) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AT7519
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AT7519 | Australia | 2014348657 | 2033-11-13 | Start Trial |
| AT7519 | Australia | 2017245411 | 2033-11-13 | Start Trial |
| AT7519 | Australia | 2019246853 | 2033-11-13 | Start Trial |
| AT7519 | Canada | 2929181 | 2033-11-13 | Start Trial |
| AT7519 | China | 105899232 | 2033-11-13 | Start Trial |
| AT7519 | Eurasian Patent Organization | 201690987 | 2033-11-13 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
